title: Growth factors as treatment options for intestinal inflammation.
abstract: On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM-CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis.
authors.affiliation: Division of Gastroenterology, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA. dieck@im.wustl.edu
authors.forename: Brian K
authors.initials: BK
authors.lastname: Dieckgraefe
authors.forename: Joshua R
authors.initials: JR
authors.lastname: Korzenik
authors.forename: Shrikant
authors.initials: S
authors.lastname: Anant
mesh_terms: D000818:Animals; D003093:Colitis, Ulcerative / Q000628:therapy*; D051526:Fibroblast Growth Factor 10 / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006133:Growth Substances / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D023421:Models, Animal; D051381:Rats; D011917:Rats, Inbred Lew
chemical_list: D051526:Fibroblast Growth Factor 10; D006133:Growth Substances; D016178:Granulocyte-Macrophage Colony-Stimulating Factor